Partial Response to PPI Treatment: The Cost to Society and the Burden to the Patient - a Study in France (REMAIN)

AstraZeneca

Status: Completed

Conditions: Gastroesophageal Reflux Disease

Study type: Observational

Funder types: Industry

Identifiers

NCT00842855

D9120N00013

Details and patient eligibility

About

The purpose of this study is to describe common treatment pathways, to collect health care utilization data and to assess symptom load as well as impact of symptoms on daily life in GERD patients who are partial-responders to PPI treatment.

Enrollment: 275 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• At least 6 month history of GERD symptoms
• Treated with unchanged optimized PPI treatment for any GERD indication during the last 4 weeks before enrollment
• Remaining GERD symptoms despite optimized PPI treatment
• Able to read and write in French, and able to comply with study requirements

Exclusion criteria

• Patients that have not experienced any GERD symptom improvement at all during PPI treatment
• Involvement in the planning or conduct of the study
• Involvement in any other observational study or in any clinical study at the time of this study or during the last 6 months
• Prior surgery of the upper GI tract

Trial design

275 participants in 1 patient group

1

Description:

274 GERD patients, partial responders to PPI treatment